From birth to menopause, gynecology is a part of women’s health specialties.
Gynecology deals with the diseases and routine physical care of the female reproductive system (ovaries, Fallopian tubes, uterus, and vagina) before and after pregnancy, and includes breast diseases (senology). Gynecology is a part of women’s health specialties that also include obstetrics, female urology and ageing specificities. Gynecology is a medico-surgical specialty, often combining hormonology to optimize the treatment of benign and malignant pathologies.
Endometriosis is one of the most serious female benign pathologies, affecting 5 to 10% of women of childbearing age. It can lead to visceral complications and a deterioration of sexual and social quality of life. Endometriosis increases the risk of infertility tenfold. Early puberty, infertility, premature birth and menopausal issues are increasingly frequent, partly due to endocrine disruptors.
Current study models, particularly in endometriosis, have numerous biases and should take the menstrual cycle and immune system into consideration. New preclinical models should be as close as possible to the human physiopathology. This could improve knowledge on topics such as myometrial contractility or the clinical consequences of menopause, and could lead to the development of new drugs.
Urosphere’s Women Health portfolio includes both in vitro assays and in vivo models, including preterm parturition models, dysmenorrhea, and menopause-induced bladder dysfunction. These can be used at various stages of preclinical research for the evaluation of drug candidates.
Urosphere participates to the development of new and safe therapeutic solutions for the treatment of gynecological pathologies and specifically for the treatment of endometriosis.
Our Services & Innovation
Urosphere’s experimental platform consists of both in vivo and in vitro pharmacological assays. We also provide access to a unique biobank of PDX preclinical models from urogenital cancers.
Finally, Urophere offers consultancy services for the preclinical development of your compounds.
Urosphere offers a range of services based on our innovative experimental models.
Development of customized models Codevelopment of therapeutic compounds Licensing.
Chantalat E. et al., 2020. International Journal of Molecular Sciences, 21(8):2815
OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor
Polh O. et al., 2018. Journal of Pharmacology and Experimental Therapeutics, 366 (2) 349-364